- Home
- NEWT vs AVIR Comparison
NEWT vs AVIR Comparison
Compare NEWT & AVIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NEWT | AVIR |
|---|---|---|
| Founded | 1998 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 400.6M | 429.1M |
| IPO Year | 2013 | 2020 |
Fundamental Metrics
Financial Performance| Metric | NEWT | AVIR |
|---|---|---|
| Price | $11.26 | $5.17 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 1 |
| Target Price | ★ $15.33 | $10.00 |
| AVG Volume (30 Days) | 218.3K | ★ 239.9K |
| Earning Date | 04-30-2026 | 05-11-2026 |
| Dividend Yield | ★ 6.00% | N/A |
| EPS Growth | ★ 11.22 | 3.00 |
| EPS | ★ 0.90 | N/A |
| Revenue | N/A | ★ $351,367,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $12.45 | N/A |
| P/E Ratio | $12.56 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.59 | $2.78 |
| 52 Week High | $15.69 | $6.45 |
Technical Indicators
Market Signals| Indicator | NEWT | AVIR |
|---|---|---|
| Relative Strength Index (RSI) | 28.12 | 47.16 |
| Support Level | $10.40 | $5.09 |
| Resistance Level | $12.43 | $5.79 |
| Average True Range (ATR) | 0.28 | 0.23 |
| MACD | -0.02 | -0.04 |
| Stochastic Oscillator | 12.55 | 23.53 |
Price Performance
Historical ComparisonAbout NEWT NewtekOne Inc.
NewtekOne Inc provides business and financial solutions under the Newtek and NewtekOne brands to the independent business owner (SMB) market. Its services are offered online and in some cases delivered by staff via video and voice calls. The company offers lending products, FDIC insured deposit products and services, payments processing, payroll services and insurance brokerage services. Loan products include SBA 7(a), ALP, SBA 504, and traditional C&I and CRE bank loans, while deposit products include consumer high yield savings accounts, high yield certificates of deposit, zero-fee business checking and business money market accounts. The company operates through four reportable segments Banking, Alternative Lending, NSBF and Payments.
About AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of oral antiviral therapies for serious viral diseases. The company's pipeline includes a regimen of bemnifosbuvir and ruzasvir for the treatment of hepatitis C virus (HCV) infection and AT-587 for the treatment of hepatitis E virus (HEV) infection.